BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32722783)

  • 21. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling.
    Mosquera Orgueira A; Díaz Arias JÁ; Cid López M; Peleteiro Raíndo A; Antelo Rodríguez B; Aliste Santos C; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; González Pérez MS; Pérez Encinas MM; Fraga Rodríguez MF; Bello López JL
    BMC Cancer; 2020 Oct; 20(1):1017. PubMed ID: 33087075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
    Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
    Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
    Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
    Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
    Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
    Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
    Dubois S; Tesson B; Mareschal S; Viailly PJ; Bohers E; Ruminy P; Etancelin P; Peyrouze P; Copie-Bergman C; Fabiani B; Petrella T; Jais JP; Haioun C; Salles G; Molina TJ; Leroy K; Tilly H; Jardin F;
    EBioMedicine; 2019 Oct; 48():58-69. PubMed ID: 31648986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
    Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
    Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
    Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
    Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?
    Scott DW
    Am Soc Clin Oncol Educ Book; 2015; ():e458-66. PubMed ID: 25993210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival.
    Cassim S; Antel K; Chetty DR; Oosthuizen J; Opie J; Mohamed Z; Verburgh E
    Pathology; 2020 Jun; 52(4):453-459. PubMed ID: 32305135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment approach to newly diagnosed diffuse large B-cell lymphoma.
    Bachy E; Salles G
    Semin Hematol; 2015 Apr; 52(2):107-18. PubMed ID: 25805590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Automatic subtyping of Diffuse Large B-cell Lymphomas (DLBCL): Raman-based genetic and metabolic classification.
    Dawiec P; Leszczenko P; Nowakowska AM; Laskowska P; Szydłowski M; Juszczyński P; Baranska M; Mrówka P; Majzner K
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 309():123795. PubMed ID: 38184880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of Digital Gene Expression Profiling for Cell-of-Origin Determination (Lymph2Cx Testing) into the Routine Work-Up of Diffuse Large B-Cell Lymphoma.
    Robetorye RS; Ramsower CA; Rosenthal AC; Yip TK; Wendel Spiczka AJ; Glinsmann-Gibson BJ; Rimsza LM
    J Hematop; 2019 Mar; 12(1):3-10. PubMed ID: 34447482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
    Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.
    Ahmed S; Glover P; Taylor J; Sha C; Care MA; Tooze R; Davies A; Westhead DR; Johnson PWM; Burton C; Barrans SL
    Br J Haematol; 2021 Feb; 192(3):599-604. PubMed ID: 33249557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.
    Araf S; Korfi K; Rahim T; Davies A; Fitzgibbon J
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1093-1102. PubMed ID: 27648481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.